Modelling the return on investment of preventively vaccinating healthcare workers against pertussis

BMC Infectious Diseases

Hero de Boer¹  Gerard Frijstein¹  Anke Hövels⁴  Marie-Josée J Mangen²  Luqman Tariq³ 

[1]Academic Medical Centre Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands

[2]Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

[3]GlaxoSmithKline BV, Zeist, The Netherlands

[4]Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

关键词: Cost;    Vaccination;    Return on investment;    Healthcare workers;    Nosocomial outbreak;    Pertussis;   

Others  :  1130608
DOI  :  10.1186/s12879-015-0800-8

 received in 2014-07-18, accepted in 2015-02-04,  发布年份 2015

【 摘 要 】

Background

Healthcare workers (HCWs) are at particular risk of acquiring pertussis and transmitting the infection to high-risk susceptible patients and colleagues. In this paper, the return on investment (ROI) of preventively vaccinating HCWs against pertussis to prevent nosocomial pertussis outbreaks is estimated using a hospital ward perspective, presuming an outbreak occurs once in 10 years.

Methods

Data on the pertussis outbreak on the neonatology ward in 2004 in the Academic Medical Center Amsterdam (The Netherlands) was used to calculate control costs and other outbreak related costs. The study population was: neonatology ward staff members (n = 133), parents (n = 40), neonates (n = 20), and newborns transferred to other hospitals (n = 23). ROI is presented as the amount of Euros saved in averting outbreaks by investing one Euro in preventively vaccinating HCWs. Sensitivity analysis was performed to study the robustness of the ROI. Results are presented at 2012 price level.

Results

Total nosocomial pertussis outbreak costs were €48,682. Direct control costs (i.e. antibiotic therapy, laboratory investigation and outbreak management control) were €11,464. Other outbreak related costs (i.e. sick leave of HCWs; restrictions on the neonatology ward, savings due to reduced working force required) accounted for €37,218. Vaccination costs were estimated at €12,208. The ROI of preventively vaccinating HCWs against pertussis was 1:4, meaning 4 Euros could be saved by every Euro invested in vaccinating HCWs to avert outbreaks. ROI was sensitive to a lower vaccine price, considering direct control costs only, average length of stay of neonates on the neonatology ward, length of patient uptake restrictions, assuming no reduced work force due to ward closer and presuming more than one outbreak to occur in 10 years’ time.

Conclusion

From a hospital ward perspective, preventive vaccination of HCWs against pertussis to prevent nosocomial pertussis outbreaks results in a positive ROI, presuming an outbreak occurs once in 10 years.

【 授权许可】

   
2015 Tariq et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Calugar A, Ortega-Sanchez IR, Tiwari T, Oakes L, Jahre JA, Murphy TV: Nosocomial pertussis: costs of an outbreak and benefits of vaccinating healthcare workers. Clin Infect Dis 2006, 42:981-8.
• [2]Sandora T, Gidengil CA, Lee GM: Pertussis vaccination for healthcare workers. Clin Microbiol Rev 2008, 21(3):426-34.
• [3]de Serres G, Shadmani R, Duval B, Boulianne N, Déry P, Douville Fradet M, et al.: Morbidity of pertussis in adolescents and adults. J Infect Dis 2000, 182:174-9.
• [4]Kurt TL, Yeager AS, Guenette S, Dunlop S: Spread of pertussis by hospital staff. JAMA 1972, 221:264-7.
• [5]Ward A, Caro J, Bassinet L, Housset B, O’Brien JA, Guiso N: Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France. Infect Control Hosp Epidemiol 2005, 26:288-92.
• [6]Weber DJ, Rutala WA: Pertussis: an underappreciated risk for nosocomial outbreaks. Infect Control Hosp Epidemiology 1998, 19:825-8.
• [7]Wright SW, Decker MD, Edwards KM: Incidence of pertussis infection in healthcare workers. Infect Control Hosp Epidemiology 1999, 20:120-3.
• [8]Baggett HC, Duchin JS, Shelton W, Zerr DM, Heath J, Ortega-Sanchez IR, et al.: Two nosocomial pertussis outbreaks and their associated costs – King county, Washington, 2004. Infect Control Hosp Epidemiol 2007, 28(5):537-43.
• [9]Zivna I, Bergin D, Casavant J, Kelley A, Mathis S, Ellison RT 3rd: Impact of Bordetella pertussis exposures on a Massachusetts tertiary care medical system. Infect Control Hosp Epidemiol 2007, 28(6):708-12.
• [10]Van der Maas N, de Melker H, Heuvelman K, van Gent M, Mooi FR. Kinkhoestsurveillance in 2013 en 2014 [Pertussis surveillance in 2013 and 2014]. RIVM Briefreport 2014–0165. Bilthoven. The Netherlands
• [11]de Greeff SC, Mooi FR, Schellekens JFP, de Melker HE: Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J 2008, 27:218-23.
• [12]Zwart B, Van Veenendaal M, Vandenbroucke-Grauls C, Kok J, Visser C: Kinkhoestuitbraak op een neonatologieafdeling. [Pertussis outbreak on a neonatology ward]. Infectieziekten Bulletin 2007, 18(3):90-1.
• [13]Niessen WJM: Het voorkomen van verspreiding van kinkhoest op een kinderafdeling van een ziekenhuis. [Preventing the spreading of pertussis on a neonatology ward of a hospital]. Infectieziekten Bulletin 2008, 19(9):272-4.
• [14]Statistics Netherlands. Available at: http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=71311ned&D1=0-1,4-5&D2=0&D3=194,219&HDR=G1,T&STB=G2&VW=T. Accessed June 2012
• [15]Hakkaart-van Roijen L, Tan SS, Bouwmans C: Update on the Dutch manual for costing in economic evaluations. Updated version 2010 [handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2010]. Institute for Medical Technology Assessment. The Dutch Healthcare Insurance Board, Diemen, The Netherlands; 2010.
• [16]Medicijnkosten [Medicine costs]. Available at: http://www.medicijnkosten.nl/. Accessed June 2012
• [17]de Greeff SC, Lugnér AK, van den Heuvel DM, Mooi FR, de Melker HE: Economic analysis of pertussis illness in the Dutch population: Implications for current and future vaccination strategies. Vaccine 2009, 27:1932-7.
• [18]de VR, Kretzschmar M, Schellekens JF, Versteegh FG, Westra TA, Roord JJ, et al.: Cost­effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual based dynamic model. PLoS One 2010, 5(10):e13392.
• [19]European Medicines Agency. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000296/human_med_000833.jsp&mid=WC0b01ac058001d124. Accessed September 2013
• [20]Z-Index. Available at: http://www.z-index.nl/. Accessed September 2012
• [21]Westra TA, de Vries R, Tamminga JJ, Sauboin CJ, Postma MJ: Cost­effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clin Ther 2010, 32(8):1479-95.
• [22]Fawke J, Whitehouse WP, Kudumala V: Monitoring of newborn weight, breast feeding and severe neurological sequelae secondary to dehydration. Arch Dis Child 2008, 93:264-5.
• [23]The Dutch Healthcare Authority. Available at: http://dbc-tarieven.nza.nl/Nzatarieven/top.do. DBC-code 140380. Accessed June 2012
• [24]Conrad online shop. Available at: http://business.conrad.nl/ce/nl/product/831184/Mondkapje-FFP1-8710E-20st. Accessed June 2012.